Rebecca Weil
Corporate Officer/Principal presso OCULIS HOLDING AG
Profilo
Rebecca Weil is currently the Chief Commercial Officer at Oculis Holding AG.
Prior to her current position, she held various roles including Director at Juvenile Diabetes Research Foundation (New York), Global Head-Marketing, Strategy & Pharmaceuticals at Bausch + Lomb Corp., and Head-Regional Franchise Asia, Middle East & Africa at Novartis AG.
From 2019 to 2023, she served as the Head-Global Marketing at Idorsia Ltd.
Before that, she was the Group Vice President & Head-Corporate Affairs at Shire Plc from 2018 to 2019.
Rebecca also worked as the Vice President & Head-Western Europe at Alcon AG.
She holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Princeton University.
Posizioni attive di Rebecca Weil
| Società | Posizione | Inizio |
|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 11/09/2023 |
Precedenti posizioni note di Rebecca Weil
| Società | Posizione | Fine |
|---|---|---|
| IDORSIA LTD | Vendite & Marketing | 01/08/2023 |
| SHIRE | Corporate Officer/Principal | 01/03/2019 |
| Juvenile Diabetes Research Foundation (New York) | Direttore/Membro del Consiglio | - |
| BAUSCH + LOMB CORPORATION | Vendite & Marketing | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formazione di Rebecca Weil
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| ALCON INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| IDORSIA LTD | Health Technology |
| BAUSCH + LOMB CORPORATION | Health Technology |
| OCULIS HOLDING AG | Health Technology |
| Aziende private | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Juvenile Diabetes Research Foundation (New York) |
- Borsa valori
- Insiders
- Rebecca Weil
